Literature DB >> 7795886

Identification and characterization of human tissue inhibitor of metalloproteinase-3 and detection of three additional metalloproteinase inhibitor activities in extracellular matrix.

N S Kishnani1, P W Staskus, T T Yang, F R Masiarz, S P Hawkes.   

Abstract

We have identified and characterized a novel human tissue inhibitor of metalloproteinase (TIMP). It is found exclusively in the extracellular matrix of a large number of cultured human cells, including: primary embryonal kidney (293), neuroblastoma (SK-N-SH), normal whole embryo (FHs 173We), cervical carcinoma (HeLa S3), colon adenocarcinoma (Caco-2), ileocecal adenocarcinoma (HCT-8), fibrosarcomas (SW 684 and Hs 913T) and normal gingival fibroblasts (GF11 and 1292). It was not detected in the conditioned media from any of these cell lines. Its apparent molecular mass of 24-25 kDa, as determined by its migration on protease-substrate gels, is intermediate between TIMP-1 (28.5 kDa) and TIMP-2 (21 kDa). Like the latter two proteins, human TIMP-3 contains intrachain disulfide bonds and displays altered electrophoretic mobility in the presence of beta-mercaptoethanol. The N-terminal, amino acid sequence of the protein is identical to that of chicken TIMP-3 (ChIMP-3), and its amino acid composition is similar. The protein is not N-glycosylated, as determined by treatment with N-glycosidase-F. Finally, it is recognized by antisera raised against pure ChIMP-3 but not by anti-human TIMP-1 or anti-human TIMP-2 antibodies. Based on these properties, we propose that this protein is TIMP-3 and is the human counterpart of ChIMP-3 (Pavloff et al., J. Biol. Chem. 267: 17321-17326, 1992). Two additional inhibitors detected in the matrix of human cell lines, designated inhibitor of metalloproteinase (IMP)-a and IMP-b, migrate with apparent masses of 29 kDa and 30 kDa. Both are N-glycosylated. A fourth inhibitor activity, which is smaller in mass than TIMP-3 and is also pecifically located in the matrix, is detectable in some cell lines.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7795886     DOI: 10.1016/0945-053x(95)90005-5

Source DB:  PubMed          Journal:  Matrix Biol        ISSN: 0945-053X            Impact factor:   11.583


  7 in total

Review 1.  Matrix metalloproteinase inhibitors.

Authors:  S M Wojtowicz-Praga; R B Dickson; M J Hawkins
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

Review 2.  TIMPs: versatile extracellular regulators in cancer.

Authors:  Hartland W Jackson; Virginie Defamie; Paul Waterhouse; Rama Khokha
Journal:  Nat Rev Cancer       Date:  2016-12-09       Impact factor: 60.716

3.  Tissue inhibitor of metalloproteinases-3 is a component of Bruch's membrane of the eye.

Authors:  R N Fariss; S S Apte; B R Olsen; K Iwata; A H Milam
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

4.  Mesenchymal stem cells regulate blood-brain barrier integrity through TIMP3 release after traumatic brain injury.

Authors:  Tyler Menge; Yuhai Zhao; Jing Zhao; Kathryn Wataha; Michael Gerber; Jianhu Zhang; Phillip Letourneau; John Redell; Li Shen; Jing Wang; Zhalong Peng; Hasen Xue; Rosemary Kozar; Charles S Cox; Aarif Y Khakoo; John B Holcomb; Pramod K Dash; Shibani Pati
Journal:  Sci Transl Med       Date:  2012-11-21       Impact factor: 17.956

5.  Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase.

Authors:  M L Fitzgerald; Z Wang; P W Park; G Murphy; M Bernfield
Journal:  J Cell Biol       Date:  2000-02-21       Impact factor: 10.539

Review 6.  Current Management and Therapeutic Strategies for Cerebral Amyloid Angiopathy.

Authors:  Yasuteru Inoue; Yukio Ando; Yohei Misumi; Mitsuharu Ueda
Journal:  Int J Mol Sci       Date:  2021-04-08       Impact factor: 5.923

7.  Systems proteomic analysis reveals that clusterin and tissue inhibitor of metalloproteinases 3 increase in leptomeningeal arteries affected by cerebral amyloid angiopathy.

Authors:  A Manousopoulou; M Gatherer; C Smith; J A R Nicoll; C H Woelk; M Johnson; R Kalaria; J Attems; S D Garbis; R O Carare
Journal:  Neuropathol Appl Neurobiol       Date:  2016-10-05       Impact factor: 8.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.